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Induction of TSC-22 by treatment with a new
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Summary We undertook the present study to clarify the molecular mechanism of the effect of a new anti-cancer drug, vesnarinone, on a
human salivary gland cancer cell line, TYS. We isolated TSC-22cDNA as a vesnarinone-inducible gene from a cDNA library constructed from
vesnarinone-treated TYS cells. TSC-22 was originally reported as a transforming growth factor (TGF)-,-inducible gene. The expression of
TSC-22 was up-regulated within a few hours after treatment with vesnarinone and was continued for 3 days. The level of TSC-22 mRNA in
TYS cells was continuously increased until the cells reached confluency. Furthermore, the induction of TSC-22by vesnarinone was inhibited
by treatment with cycloheximide. When we treated the cells with an antisense oligonucleotide against TSC-22 mRNA under quiescent
conditions, the antisense oligonucleotide stimulated the growth of TYS cells; however, under growing conditions the antisense oligonucleotide
did not affect cell growth. Furthermore, the antisense oligonucleotide suppressed the antiproliferative effect of vesnarinone. These results
suggest that TSC-22 may be a negative growth regulator and may play an important role in the antiproliferative effect of vesnarinone.
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Vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)- 1-piper-
azinyl]-2(1H)-quinolinone) was originally developed as an oral
inotropic agent and has been used for the treatment of chronic
heart failure in Japan (Asanoi et al, 1987). It has been reported
recently that vesnarinone has an antiproliferative and differentia-
tion- and apoptosis-inducing activity in several tumour cells in
vitro and in vivo (Sato et al, 1994, 1995). Therefore, vesnarinone
has been subjected to a clinical phase study as an anti-cancer drug
in the treatment of several solid tumours, including head and neck
cancer, in Japan. We have recently reported the up-regulation of
TGF-J1 and p21tafJ mRNA and their proteins in a human salivary
gland cancer cell line after treatment with vesnarinone (Sato et al,
1997). However, the molecular mechanism ofthe antiproliferative
effect ofvesnarinone is not fully understood.
A human salivary gland cancer cell line, TYS, was established
in our laboratory (Yanagawa et al, 1986). We have shown that
vesnarinone markedly inhibits the growth ofTYS cells in vitro and
in vivo (Sato et al, 1994, 1995). In this study, we attempted to
clarify the molecular mechanism of the effect of vesnarinone on
TYS cells. We isolated TSC-22 cDNA as a vesnarinone-inducible
gene by a random sequencing method. TSC-22 was reported as
a transforming growth factor (TGF)-p or follicle-stimulating
hormone (FSH) inducible transcriptional regulator containing a
leucine zipper-like structure in mice (Shibanuma et al, 1992), rats
(Hamil and Hall, 1994) and humans (Jay et al, 1996). We exam-
ined the expression of TSC-22 mRNA in detail in vesnarinone-
treated or untreated TYS cells. Furthermore, we tested the effect of
an antisense oligonucleotide against human TSC-22 mRNA on
vesnarinone-treated or untreated TYS cells.
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MATERIALS AND METHODS
Cell culture
TYS cells were grown in Dulbecco's modified eagle medium
(DMEM; Gibco, Gaithersburg, MD, USA) supplemented with
10% fetal calf serum (FCS; Bio-Whittaker, Walkersville, MD,
USA), 100,g ml' streptomycin, 100 U ml-' penicillin (Gibco)
and 0.25 ,ug ml' amphotericin B (Gibco) in a humidified atmos-
phere of95% air and 5% carbon dioxide at 37°C.
Treatment of the cells with vesnarinone
Vesnarinone was kindly provided by Otsuka Pharmaceutical
Company, Tokyo. Vesnarinone was dissolved in DMSO (Sigma,
StLouis, MO, USA) at a concentration of 10 mg ml-' as a first stock
solution and then the first stock solution was diluted with the
complete culture medium described above to the desired concentra-
tion (0, 0.1, 1, 10, 50,g ml-'). The antiproliferative activity of
vesnarinone stored in the medium was stable for at least 1 month at
4°C (data not shown). We evaluated the in vitro antiproliferative
effect of vesnarinone on cancer cells using MTh [3-(3,4-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Carmichael
et al, 1987). Cells were seeded on 96-well plates (Falcon; Becton
Dickinson Labware, Lincoln Park, NJ, USA) at 2 x 103 cells per
well in DMEM containing 10% FCS. After 24 h, cells were placed
in DMEM containing 10% FCS with several concentrations of
vesnarinone (0, 0.1, 1, 10 and 50,g ml-'). After 2 and 4 days, the
number ofcells was quantitated by an assay using MIT (Sigma).
Cell cycle analysis
TYS cells were cultured in the presence or absence of 50 gg ml'
ofvesnarinone for 24 h, 48 h and 72 h, and the cells were collected
in conical tubes (Falcon). Then, the cells were fixed with 70%
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ethanol and washed with phosphate-buffered saline. After treat-
ment with 100gg ml-' of RNaseA (Sigma), the cells were stained
with 40 ,ug ml-' propidium iodide (Molecular probes, Eugene, OR,
USA), and the cell cycle was analysed by a digital flow cytometry
system EPICS (Coulter, Miami, FL, USA).
RNA isolation
Total cytoplasmic RNA was prepared by lysing cells in hypotonic
buffer containing Nonidet p-40 (Sigma), followed by removal of
the nuclei. Poly(A)+ RNA was prepared from total cytoplasmic
RNA using two cycles ofoligo(dT)-cellulose chromatography.
Construction of cDNA library
Five micrograms of poly(A)+ RNA, which was isolated from TYS
cells treated withvesnarinone (50 ,ug ml-') for 3days and was reverse
transcribed with Moloney-murine leukaemia virus reverse transcrip-
tase (M-MLV) (Gibco) using oligo(dT)-Xhol primer/linker
(Stratagene, La Jolla, CA, USA). Second-strand cDNA was synthe-
sized using a cDNA synthesis kit purchased from Stratagene and
ligated with the EcoRI adapter according to the manufacturer's
recommendations. AfterXhoIdigestion ofthesynthesizedcDNA, the
cDNA was ligated with thecloning vectorZAPExpress (Stratagene),
which had been digested with EcoRI and Sall. The cDNA was then
inserted in antisense orientation from eukaryotic and prokaryotic
promoter in the vector. A primary cDNA library contained about 1.5
x 105 independent clones and was 90% recombinant. The ZAP
Express library was used after one round ofamplification.
Random sequencing
Randomly selected pBK-CMV library-transformed colonies were
picked up by tooth pick and cultured overnight in 6 ml of LB
medium containing 50 jg ml-' kanamycin. The phagemid was
extracted by the alkaline lysis method and half of the phagemid
was digested with EcoRI and PstI to excise the cDNA inserts.
Most inserts ranged in size from 0.5 kb to 2.0 kb. The cDNA
inserts were purified from agarose gel by Gene Clean kit II (Bio
101, Vista, CA, USA) and subsequently used as a probe for
Northern blot analysis. The remaining half of the phagemid was
subjected to sequencing analysis. DNA sequence was determined
by the dideoxy chain-termination method using FITC-labelled
primers and Takara Taq Cycle Sequencing kit or Amersham
Thermo Sequenase Cycle Sequencing Kit (Amersham, Arlington
Heights, IL, USA). The electrophoresis and scanning were
performed using a Shimadzu DSQ-500 DNA sequencer
(Shimadzu, Kyoto, Japan). Approximately 200-300 bp of the
DNA sequence can be detected for each clone. The GenBank and
EMBL databases were searched for overall nucleic acid homolo-
gies by the BLAST program via the Internet. The entire nucleotide
sequence of human TSC-22 cDNA was examined at least
three times.
Polymerase chain reaction (PCR)
Polymerase chain reaction was performed as follows: the final
concentration of dNTPs and primers in the reaction mixture was
200gM and 1 gM respectively. Taq DNA polymerase (Takara) was
added to the mixture at a final concentration of0.05 Upl-l and the
reaction was carried out in the thermal sequencer (Iwaki glass,
Osaka, Japan) under the following conditions: 94°C for 3 min and
then 94°C for 1 min; 55°C for 1.5 min; 72°C for 2.5 min for 30
cycles and an extension of72°C for 4 min.
Isolation of nearlyfull-length human TSC-22 cDNA
A clone (pBK-CMV-hTSC-22-3' end) obtained from random
sequencing contained only 1313 bp ofhuman TSC-22 cDNAfrag-
ment, and did not include a complete open reading frame.
Therefore, we attempted to clone full-length human TSC-22
cDNA. One hundred nanograms of the pBK-CMV library
containing vesnarinone-treated TYS cDNA in antisense orienta-
tion form CMV promoter was amplified by the primers DPI (5'-
agccagtctgcagctgggcctgaa-3') and the T7 RNA polymerase
promoter sequence (5'-taatacgactcactataggg-3'), which should be
located up-stream ofthe cDNA inserts in the vector. Subsequently,
the PCR products were subjected to the second-round PCR.
The primers used for the second-round PCR were DP2 (5'-
tctgcagctgggcctgaaactgggc-3'), which is located 7 bp upstream of
DPI primer and contains the PstI site, and mUP (5'-atctagtt-
tgaaccaggctg-3'), whose sequence is obtained from mouse and rat
TSC-22 sequence 92 bp upstream from the translation initiation
codon of TSC-22 in mouse or 84 bp upstream in rat (Shibanuma et
al, 1992; Hamil and Hall, 1994). The second-round PCR product
containing human TSC-22-5' end was subcloned into pUCJ9
vector (pUCJ9-hTSC-22-5' end). PstI-digested hTSC-22-3' end
fragment from pBK-CMV-hTSC-22-3' end was ligated into the
pUCJ9-hTSC-22-5'end, which was predigested with PstI. Nearly
full-length human TSC-22 cDNA was isolated at this point.
Northern blot analysis
Cytoplasmic RNA (20 jg) was electrophoresed onto a formalde-
hyde/1.0% agarose gel and blotted onto a nylon filter (Hybond N+;
Amersham). The nylon filter was hybridized with 32P-labelled
cDNA probes in 50% formamide, 5 x saline-sodium phosphate-
EDTA, 0.1% sodium sulphate dodecyl (SDS), 5 x Denhardt's solu-
tion and 100 jig ml-' salmon sperm DNA at 42'C for 15-20 h.
Extensive washing was performed: twice with 0.1 x standard
saline citrate-0.5% SDS at room temperature and once at 50°C for
40 min with the same washing buffer. Subsequently, the filter was
exposed to radiographic film with an intensifying screen at -70°C.
Theprobes used were a 1.2-kb 3' end ofhuman TSC-22 cDNA, an
875-bp fragment of human p2Jwafl cDNA isolated in our labora-
tory (Sato et al, 1997) and a 2.1-kb XhoI-XhoI fragment of
pHF/3A-1 for human ,B-actin (American Type Culture Collection,
Rockville, MD, USA). Densitometric analysis of the signals was
performedby NIH Image 1.44 program and/or BAS-2000 II image
analysing system (Fuji photo film, Yokohama, Japan).
Western blotting and enzyme-linked immunosorbent
assay (ELISA)
One hundred micrograms of protein samples prepared from TYS
cells was electrophoresed on an SDS-polyacrylamide gel. Proteins
from gels were transferred to a nitrocellulose membrane (Bio-
Rad). TSC-22 protein on the membrane was detected with an
affinity-purified anti-glutathione-S-transferase (GST)-TSC-22
fusion protein rabbit polyclonal antibody, which was generated
recently in our laboratory (unpublished data), and an Amersham
ECL kit (Amersham).
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Figure 1 Effect of vesnarinone on in vitro growth of TYS cells. The values
shown are the mean of six determinations. The error bars indicate the
standard deviation. *P < 0.01 compared with that of control by one-way
analysis of variance. Concentration of vesnarinone in the medium (,ug ml-');
,0; -+-, 0.1; {-,11.0; -0-,10; -U-, 50
*800 41 iss ll,-. r IN
Up-regulation ofTSC-22 protein in TYS cells by treatment with
vesnarinone was measured by solid-phase ELISA, which was
developed in our laboratory. One hundred micrograms of protein
samples was added to 96-well plates (Falcon) and incubated for
3 h at room temperature. The primary antibody (affinity-purified
anti-GST-TSC-22 fusion protein rabbit antibody; 1:2000) was
added to the wells and incubated for 3 h at room temperature.
After washing with phosphate-buffered saline, HRP-conjugated
goat anti-rabbit IgG (Amersham; 1:500) was added to the wells
and incubated for 1 h at room temperature. Then, 100 ,ul of TMB
(3,3',5,5'-tetramethylbenzidine; Sigma, 0.1 mg ml-1) solution was
added to the wells followed by incubation for 10 min. The reaction
was stopped using 50 ,ul of 1 M sulphuric acid and the absorbance
was measured at 450 nm.
Treatment of TYS cells with antisense oligonucleotide
against human TSC-22
An antisense phosphorothioate oligonucleotide (5'-tgggattt-
CATgcaattgca-3') and a sense phosphorothioate oligonucleotide
(5'-tgcaattgcATGaaatccca-3') were synthesized. The oligonucleo-
tides were added to the medium at 10 ,UM with or without lipo-
fectin reagent (Gibco). Lipofectin reagent was slightly toxic to
TYS cells and was not effective at transducing the oligonu-
cleotides into the cells. Therefore, we decided to use the oligonu-
cleotides without the lipofectin reagent. The oligonucleotides were
directly added to the culture medium when the cells reached
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Figure 2 Cell cycle analysis of TYS cells. TYS cells were cultured in the presence or absence of 50igg ml-' vesnarinone for 24 h, 48 h and 72 h. After staining
with 40 9g ml-' propidium iodide, the cell cycle was analysed by a digital flow cytometry system
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confluence or when the cells were growing rapidly. The number of
the cells were evaluated by MTT assay.
RESULTS
Effect of vesnarinone on in vitro cell growth
We tested the effect of vesnarinone at four concentrations on in
vitro cell growth ofTYS cells. The effect of0.1-10 I-gml-1 vesnar-
inone was marginal; however, 50 ,ug ml-1 vesnarinone markedly
suppressed the growth of TYS cells (Figure 1). The growth-
inhibitory effect of vesnarinone on TYS cells appeared to be
cytostatic but not cytocidal. TYS cells treated with 50 g ml1
vesnarinone were enlarged and stopped the cell division but did not
detach from the bottom of the culture dish (data not shown).
Dimethylsulphoxide (DMSO), which was used as a vehicle for
vesnarinone, slightly inhibited the growth of TYS cells, but the
inhibitory effect ofDMSO is much lower than that ofvesnarinone.
When we treated the cells with 100 jg ml-1 ofvesnarinone, vesnar-
inone was crystallized inthe medium. Therefore, wedecided to use
the concentration of 50 jg ml vesnarinone, which showed a
growth-inhibitory effect on TYS cells, for further investigation.
Cell cycle analysis
Cell cycle changes associated with vesnarinone treatment in
TYS cells were analysed using flow cytometry. Fifty per cent
of TYS cells in the untreated group existed at S and G2/M phase
24 h after changing the medium. However, after48 h and 72 h, the
proportion ofcells at S and G2/M phase was gradually decreased in
the untreated group, probably because of the consumption of
growth factors in the medium and/or growth arrest induced by
contact inhibition (Figure 2 and Table 1). In the vesnarinone-
treated group, the proportion ofthe cells at S and G2/M phase 24 h
after addition ofthe drug was much lower than that in the control
group (Figure 2 and Table 1). After more than 48 h ofexposure to
vesnarinone, most of the TYS cells were arrested at G1 phase
(Figure 2 and Table 1).
Isolation of human TSC-22 cDNA
We sequenced 107 clones randomly from a cDNA library that was
constructed from vesnarinone-treated TYS cells. Approximately
64% of the clones were known genes, 18% were functionally
unknown but were registered in the database and 18% were
unknown genes. In the known genes, the proportion of house-
keeping genes in our vesnarinone-treated TYS library was lower
than that in the commonly constructed cDNA library. Vesnarinone
treatment may reduce the expression of housekeeping genes and
relatively increase the expression of genes associated with cell
growth and differentiation as well as apoptosis in TYS cells.
Approximately 30% ofthe known genes appeared to be associated
with cell growth and differentiation as well as apoptosis, such as
TSC-22, HSC70, CKJ9, SOS, NGFR-related lymphocyte activa-
tion molecule, IL-6, TAFIIA, elongation factor-ly, IL-J/TNF
inducible EST, DNA-binding protein A, Anexin II, DNA-depen-
dent protein kinase catalytic subunit, rab-GDI, SUIJ translation
initiation factor, lysosomal protective protein, TNF-a inducible
protein B12, ADP-ribosylation factor, phospholipase A2, and 13-
kDa differentiation-associated protein. We compared the expres-
sion of the above known genes and the isolated unknown genes
Table 1 Cell cycle analysis of TYS cells
Untreated TYS Vesnarinone-treated TYS
24h 48h 72h 24h 48h 72h
GJ/G, 50.5% 56.5% 72.7% 76.2% 81.8% 92.0%
S 24.6% 17.6% 11.1% 10.3% 7.2% 2.0%
GJM 20.3% 21.7% 13.3% 11.0% 6.4% 4.7%
TYS cells were cultured in the presence or absence of 50 gg ml-'
vesnarinone for 24 h, 48 h or 72 h. The cells were stained with propidium
iodide and the cell cycle was analysed by a digital flow cytometry system.
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Figure 3 The effect of vesnarinone on the mRNA expression of TSC-22 in
TYS cells. (A) Cytoplasmic RNA was prepared from vesnarinone-treated
(50 ,ug ml-') TYS cells (+) or untreated cells (-). RNA (20 igg per lane) was
fractionated on 1.0% denaturing agarose gel, transferred to a nylon filter and
hybridized to 32P-labelled probes for human TSC-22and /3-actin. (B)
Densitometric scanning of the autoradiographs shown in A *, control; Z, vesnarinone
between untreated TYS cells and vesnarinone-treated TYS cells
by Northern blotting (data not shown). In these genes, the mRNA
expression of TSC-22 was apparently up-regulated in the vesnari-
none-treated TYS cells. However, the expression of other genes
was decreased or unchanged after treatment with vesnarinone in
TYS cells. TSC-22 was reported as a TGF-f or FSH-inducible
putative transcriptional regulator containing a leucine zipper-like
structure. Nucleotide sequence analysis revealed that the overall
similarity between the human TSC-22 gene and mouse or rat TSC-
22 was only 79%. However, the sequence in the coding region of
human TSC-22 was almost identical (92%) to that of mouse or rat
TSC-22. Moreover, the predicted human TSC-22 protein was also
almost identical to mouse or rat TSC-22 protein (98%). Human
TSC-22 protein is composed of 144 amino acids, but mouse and
rat TSC-22 protein contained 143 amino acids (Shibanuma et al,
1992; Hamil and Hall, 1994). One serine residue was inserted at
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Figure 4 Short-time course of the mRNA induction of TSC-22by vesnarinone and TGF-fl in TYS cells. (A) Cytoplasmic RNA was prepared from vesnarinone
(50 ,ug ml-')- or TGF-fl (1 ng ml-')-treated TYS cells at indicated time (1, 2, 6, 12 or 24 h). RNA (20 ,ug per lane) was fractionated on 1.0% denaturing agarose gel,
transferred to a nylon filter and hybridized to 32P-labelled probes for human TSC-22and P-actin. (B) Densitometnc scanning of the autoradiographs shown in A
codon 43 in human TSC-22 and serine residue at codon 141 in
mouse and rat (codon 142 in human) was replaced by proline
residue. A putative leucine zipper-like structure from leucine-77 to
leucine-98 was conserved in human TSC-22 protein. The
nucleotide sequence of human TSC-22 obtained from a salivary
gland cancer cell line in this study was completely identical to that
obtained from a human embryo by Jay et al (1996).
Induction of TSC-22 mRNA on TYS cell by treatment
with vesnarinone
The expression of TSC-22 mRNA was examined by Northern blot
analysis. We detected an approximately 1.8-kb TSC-22 mRNA in
TYS cells. The level ofTSC-22 mRNA in TYS cells was continu-
ously increased until the cells reached confluence (Figure 3).
Furthermore, the TSC-22 mRNA expression in TYS cells was
markedly enhanced by treatment with 50 jg ml- vesnarinone
(225% of control at day 1, 164% of control at day 2 and 125% of
control at day 3) (Figure 3). The induction of TSC-22 mRNA was
continued for at least 3 days after the addition ofthe drug. We have
already reported the up-regulation by vesnarinone of TGF-PJ and
p2Iwafl mRNA and protein in TYS cells, and the growth-inhibitory
effect ofTGF-P1 on TYS cells (Sato et al, 1997). We therefore,
analysed the short time-course induction of TSC-22 by vesnari-
none andTGF-f31. As shown in Figure 4, the expression ofTSC-22
was slightly enhanced by vesnarinone in a few hours, however
marked induction of TSC-22 mRNA was observed at 24 h after the
addition of vesnarinone. In contrast, very rapid induction of TSC-
22 mRNA was observed after treatment with TGF-31 (Figure 4).
To clarify whether or not the induction of TSC-22 and p2Jwafl
mRNA was a direct effect ofvesnarinone, we examined the effect
of a protein synthesis inhibitor, cycloheximide, on the induction of
the genes. The expression of TSC-22 mRNA was markedly
enhanced by treatment with 10 gg ml-1 cycloheximide, probably
as a result of accumulation of mRNA; however, induction of the
TSC-22 gene by vesnarinone was inhibited by treatment with
cycloheximide (Figure 5). In contrast, the induction of p2lwafl by
vesnarinone was not inhibited by treatment with cycloheximide
(Figure 5). These results indicate that the induction of TSC-22
mRNA by vesnarinone in TYS cells is mediated mainly by the
production of proteins and that the induction of p2lwafl is a direct
effect ofvesnarinone.
Detection of TSC-22 protein
We detected two bands of TSC-22 protein at 20 kDa and 18 kDa
using Western blotting (Figure 6A). A slow mobile band may be a
phosphorylated form of TSC-22 protein. Using Western blotting,
we could not demonstrate a clear difference in the expression of
TSC-22 protein between vesnarinone-treated and untreated TYS
cells (data not shown). Using solid-phase ELISA, however, it was
demonstrated that TSC-22 protein in vesnarinone-treated TYS
cells was up-regulated when compared with that in untreated
control (Figure 6B).
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Figure 5 Effect of cycloheximide on the induction of TSC-22and p21wafl
in TYS cells. (A) Cytoplasmic RNA was prepared from vesnarinone
(50 gg ml-')-treated or untreated TYS cells at the indicated times (2, 4 and
6 h) in the presence or absence of 10 gg ml-' cycloheximide. RNA (20 ,ug per
lane) was fractionated on 1.0% denaturing agarose gel, transferred to a nylon
filter and hybridized to 32P-labelled probes for human TSC-22, p21wa-f and
,B-actin. (B) Densitometric scanning of the autoradiographs shown in A
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Effect of antisense oligonucleotide against human
TSC-22 mRNA on vesnarinone-treated or untreated
TYS cells
Treatment of TYS cells with a sense oligonucleotide at 10 gM
slightly inhibited the growth of the cells, probably because of the
non-specific cytotoxicity ofhigh-dose oligonucleotides (Figure 7).
However, treatment with an antisense oligonucleotide at the same
concentration stimulated the growth of TYS cells (Figure 7,
P<0.01; one-factor analysis of variance). Furthermore, the anti-
sense oligonucleotide suppressed the antiproliferative effect of
vesnarinone on TYS cells (Figure 7). In this experiment, the treat-
ment of TYS cells with vesnarinone was started when the cells
reached confluence, therefore the antiproliferative effect of
vesnarinone against TYS cells was not as strong as that shown in
Figure 1. In contrast, when we treated the TYS cells with the anti-
sense oligonucleotide in the presence or absence of vesnarinone
under low-density culture conditions (2 x 103 per well), we could
not demonstrate the clear effect of the antisense oligonucleotide
Figure 6 (A) Detection of TSC-22 protein in TYS cells by Western blotting.
An aliquot (100 jg) of protein from TYS cells (TYS) or 100 ng of purified
recombinant GST-TSC-22 protein (GST-TSC-22) was subjected to
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose and
stained with affinity-purified anti-GST-TSC-22 antibody. Positions of
molecular weight markers (kDa) are indicated. (B) Detection of TSC-22
protein in the cells by solid-phase ELISA. Control, 100 igg of protein prepared
from untreated TYS cells; DMSO, 100 jg of protein prepared from TYS cells
treated with 0.5% of DMSO for 48 h; ves, 100 jg of protein prepared from
TYS cells treated with 50 jg ml-1 vesnarinone for 48 h. Values are means of
duplicate determination. Data are representative of two separate experiments
with similar results. Inset shows a standard curve for the solid-phase ELISA
using GST-TSC-22 fusion protein as an antigen
(data not shown). As shown in Figure 3, the expression ofTSC-22
mRNA in TYS cells was very low under a low-density culture
conditions but gradually increased until the cells reached conflu-
ence. Therefore, the antisense oligonucleotide was not effective
under low-density culture conditions but was effective under high-
density culture conditions.
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Figure 7 Effect of an antisense oligonucleotide against human TSC-22
mRNA on vesnarinone-treated or untreated TYS cells. The values shown are
the mean of six determinations. The error bars indicate the standard
deviation. Data are representative of three separate experiments with similar
results. Statistically significant was analysed by one-way analysis of variance
DISCUSSION
The level of TSC-22 mRNA was highly proportional to the cell
density and the cell cycle in culture. The level of TSC-22 mRNA
was low in a growing condition; however, the mRNA level was
markedly increased when the cells reached confluence.
Vesnarinone induced the expression of TSC-22 mRNA in TYS
cells and markedly suppressed the cell growth by arresting the cell
cycle atGI phase. Moreover, an antisense oligonucleotide against
TSC-22 mRNA stimulated the growth of TYS cells after the cells
reached confluence and suppressed the antiproliferative effect of
vesnarinone. Thus, TSC-22 may negatively regulate the growth of
a salivary gland cancer cell line and may mediate, at least in part,
the growth-inhibitory signals from vesnarinone in TYS cells. The
amino acid sequence of human TSC-22 was 98% identical to the
mouse and rat sequence (one amino acid insertion and one amino
acid replacement), although only 79% nucleotide sequence was
identical in overall cDNA sequence (Shibanuma et al, 1992; Hamil
and Hall, 1994; Jay et al, 1996) This high amino acid sequence
conservation beyond the species indicates an essential role ofTSC-
22 in regulating cellular activities such as cell growth, differentia-
tion and apoptosis. We detected 18-kDa and 20-kDa proteins in
TYS cells by Western blotting using a specific antibody against
recombinant human TSC-22 protein. Thus, the TSC-22 gene may
produce the functional protein and may in fact regulate cell growth.
The mRNA expression of TSC-22 was slightly enhanced by
vesnarinone in a few hours; however, apparent induction ofTSC-22
mRNA was observed 24 h after the addition of vesnarinone and
continued for at least 3 days. In contrast, very rapid induction of
TSC-22 mRNA was observed after treatment with TGF-,BI in TYS
cells. Shibanuma et al (1992) and Hamil and Hall (1994) reported
that the induction of TSC-22 in mouse and rat cells by TGF-,13 or
FSH was rapid but transient, similar to that of Jun and Fos. We
have reported that vesnarinone stimulates the production of TGF-
P1 protein in TYS cells (Sato et al, 1997). Therefore, we concluded
that, at least in our human cell system, the expression of TSC-22
mRNA was slightly enhanced by vesnarinone in a few hours via
its direct action and was apparently induced after 24 h, probably
mediated by the production ofother proteins, such as TGF-3.
Recently, we have reported that TYS cells contain the mutated
pS3 gene and that both vesnarinone and TGF-51 enhanced the
expression ofp21 4'afl mRNA and its protein (Sato et al, 1997). We
therefore attempted to clarify the association of TSC-22 in the
induction of p21l"afl in TYS cells. However, vesnarinone induced
p21lwafl mRNA without any protein synthesis (Fig. 5), and treat-
ment with antisense oligonucleotide against TSC-22 mRNA did
not affect the induction ofp21wafl mRNA by vesnarinone (data not
shown). Chin et al (1996) reported that p2lwafJ was induced as an
immediate-early gene in A431 cells by EGFR-STAT1 system.
Thus, p21aafl was induced like an immediate-early gene in TYS
cells as well, and TSC-22 may not lie upstream of p2hwafl in an
antiproliferative pathway of vesnarinone.
As Shibanuma et al (1992) and Hamil and Hall (1994) previ-
ously mentioned in their papers about mouse and rat TSC-22
protein, human TSC-22 protein is also lacking the basic region at
the N-terminus ofthe leucine zipperdomain. Thus, human TSC-22
may interact with basic leucine zipper transcriptional factors and
may act as a dominant-negative regulator, like CHOP (Ron and
Habener, 1992) or IP-1 (Auwerx and Sassone-Corsi, 1991). CHOP
is a homologue of the C/EBP family oftranscriptional factors and
is also known as GADD (growth arrest and DNA damage) 153
(Fomace et al, 1989; Park et al, 1992); it acts as a dominant nega-
tive inhibitor of C/EBP (Ron and Habener, 1992; Barone et al,
1994a). Expression of the CHOP (GADD153) gene is induced by
several agents that cause growth arrest or DNA damage (Fomace
et al, 1989). Additionally, a dominant-negative regulator, Id, is a
helix-loop-helix protein lacking the basic DNA-binding region,
and is well studied in regulating cell growth and differentiation
(Benezra et al, 1990). Ids (Idl, Id2, 1d3 and Id4) specifically bind
to the basic helix-loop-helix proteins, such as MyoD, E2A, E12,
and E47, and inhibit their ability to bind DNA (Riechmann et al,
1994). Ids regulate differentiation in several cellular systems,
including myogenesis (Benezra et al, 1990; Kurabayashi et al,
1994), neurogenesis (Nagata and Tadokoro, 1994) and haematoge-
nesis (Sun, 1994) and cell growth (Barone et al, 1994b).
Currently, we are investigating the tumour-suppressor function
and differentiation- and apoptosis-inducing capability of TSC-22
in human salivary gland cancer cells, and are looking for the target
proteins of TSC-22 by the yeast two-hybrid screening system.
Futhermore, we are investigating the expression of TSC-22 in
human salivary gland cancer tissue before treatment and the alter-
ation of TSC-22 expression during treatment, and trying to use
TSC-22 as a sensitivity marker or a prognostic marker for vesnari-
none treatment.
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